Astria Therapeutics to Participate in Upcoming Investor Conferences
06 Septembre 2023 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema (HAE) and focused on life-changing therapies for rare
and niche allergic and immunological diseases, today announced that
it will be participating in two upcoming investor conferences:
- Noah Clauser, Chief Financial Officer, will present a corporate
overview and information on STAR-0215 at the H.C. Wainwright 25th
Annual Global Investment Conference on Tuesday, September 12th at
10:00am ET in New York, NY.
- Astria will be participating in the Morgan Stanley 21st Annual
Global Healthcare Conference on September 13th in New York,
NY.
A webcast of the presentation at H.C. Wainwright can be accessed
at the following link:
https://journey.ct.events/view/8b0ad478-68ce-4168-8d0a-2383781f3a0c.
An archived replay of the presentation will be available in the
investors section of www.astriatx.com for 30 days following the
event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in clinical development for the
treatment of hereditary angioedema. Learn more about our company on
our website, www.astriatx.com, or follow us on Twitter and
Instagram @AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906961880/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024